Amneal names Allergan vet president
Amneal Pharmaceuticals and Impax Labs have new leadership. The Bridgewater, N.J.-based Amneal has named Robert Stewart president, effective Jan. 25, 2018. Stewart was most recently COO at Allergan.
Once Amneal’s acquisition of Impax closes, Stewart will become president and CEO of the combined Amneal Pharmaceuticals, the company said. Also after the close, Impax president and CEO Paul Bisaro will be named executive chairman, with current Amneal co-CEOs and co-founders Chirag Patel and Chintu Patel assuming the titles of co-chairmen of the combined company’s board of directors.
“We are excited that Rob will be joining Amneal. He is a great leader to inspire our team as we prepare for the expected combination with Impax and next phase of our growth in becoming a leading, affordable, healthcare company” Chirag Patel said.
Stewart will work with Chirag and Chintu Patel to lead the company’s current business, as well as play a key role in overseeing pre-integration planning for the planned Impax combination, expected to closein the first half of 2018.
“I am honored and excited to work with the Amneal and Impax teams,” Stewart said. “The combination creates a dynamic leader in generics and specialty pharmaceuticals, with a deep and rich pipeline of products and integrated global manufacturing platform for strong continued profitable growth. I look forward to leading the teams and helping the organization achieve its long-term goals.”
Stewart joined Allergan, which was then Watson, as vice president of global operations in 2009. He held various titles, including president of generics and global operations and president of global operations. Before Allergan, he held various positions at Abbott Labs and Hoffman La-Roche.
“Rob is a highly respected leader with a wealth of pharmaceutical expertise which will further enhance our team of world-class leaders focused on creating value for patients, customers, employees and shareholders,” Chintu Patel said.
AmerisourceBergen Foundation launches support program combating opioid abuse
The AmerisourceBergen Foundation has announced the launch of a municipal support program aimed towards the safe disposal of opioids. The Valley Forge, Pa.-based company aims to do this by providing communities nationwide with resources to deactivate expired or unused medications.
“The epidemic of opioid abuse demands action, attention and a collaborative approach. The safe disposal of unused prescription medications is a critical component in combating the issue, as it reduces the risk for misuse, abuse, and diversion,” Gina Clark, president of the AmerisourceBergen Foundation, and executive vice president and chief communications & administration officer at AmerisourceBergen said. “At AmerisourceBergen and the AmerisourceBergen Foundation, we are united in our responsibility to create healthier futures. Through this program, we will provide communities with the resources needed to deactivate prescription medications in a safe and effective manner, and help advance their efforts to prevent opioid abuse.”
As part of the program, the AmerisourceBergen Foundation will distribute drug deactivation resources to municipalities that are actively working to prevent opioid abuse and misuse, the company said. These disposable resources will use a technology that will deactivate opioids when combined with water.
In order to support these efforts, AmerisourceBergen will leverage its network of distribution centers to provide communities across the country with access to the drug deactivation resources. More information about the program and foundation can be found on the company’s website.
Pfizer gets FDA nod for second Remicade biosimilar
The Food and Drug Administration recently approved Pfizer’s Ixifi (infliximab-qbtx), the company’s second approved biosimilar of Janssen’s Remicade. The biosimilar was approved for all of Remicade’s indications, including Crohn’s disease, ulcerative colitis, rheumatoid arthritis and plaque psoriasis, among others.
The approval follows the April 2016 launch of its first Remicade biosimilar Inflectra. According to reports, Pfizer has said it has no plans to launch Ixifi in the United States.
Outside the United States, Pfizer markets Inflectra, Retacrit (epoetin zeta) and Nivestim (filgrastim). It said that its biosimilars pipeline includes 13 distinct biosimilar molecules in various stages of development.